Apple To Launch New Low-Cost iPhone SE
Apple (AAPL) is expected to launch a new version of its low-cost iPhone SE at a product event today (Feb. 19).The exact item to be revealed at Apple’s event isn’t known. Apple CEO Tim Cook teased the upcoming event on social media last week without providing any details. However, many analysts are speculating that Apple will unveil its newest iPhone SE model, which is a less expensive version of the company’s signature smartphone.Unlike more expensive iPhone models, the SE still has a button on the front and a single camera lens on the back. The SE also uses an A15 Bionic microchip that is less powerful than the A19 chip found in the high-end iPhone 16, which is the newest version of the popular smartphone.The iPhone SE was first introduced in 2016 and previously updated in 2020 and 2022. The new version of the iPhone SE that’s likely to be revealed today is expected to include the removal of the home button.Other changes that are anticipated include the introduction of Apple’s artificial intelligence (A.I.) software, known as “Apple Intelligence,” along with a more powerful processor.There are unconfirmed reports that the new iPhone SE could be Apple’s first device with an in-house cellular modem chip, replacing components previously made by Qualcomm (QCOM). Analysts are estimating that the new base model iPhone SE will cost $499 U.S., or less than half the starting price of the iPhone 16 base model. The stock of Apple has risen 35% over the last 12 months to trade at $244.47 U.S. per share.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


